BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32638462)

  • 21. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
    Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
    Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador.
    Campos NG; Alfaro K; Maza M; Sy S; Melendez M; Masch R; Soler M; Conzuelo-Rodriguez G; Gage JC; Alonzo TA; Castle PE; Felix JC; Cremer M; Kim JJ
    Prev Med; 2020 Feb; 131():105931. PubMed ID: 31765712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.
    de Bekker-Grob EW; de Kok IM; Bulten J; van Rosmalen J; Vedder JE; Arbyn M; Klinkhamer PJ; Siebers AG; van Ballegooijen M
    Cancer Causes Control; 2012 Aug; 23(8):1323-31. PubMed ID: 22706692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
    Pedersen K; Burger EA; Sy S; Kristiansen IS; Kim JJ
    Gynecol Oncol; 2016 Nov; 143(2):326-333. PubMed ID: 27542966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis.
    Pedersen K; Sørbye SW; Kristiansen IS; Burger EA
    BJOG; 2017 Feb; 124(3):474-484. PubMed ID: 27264207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M; Mrhar A; Kos M
    Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
    Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
    J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
    Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
    Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
    Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
    Jansen EEL; Ivanuš U; Jerman T; de Koning HJ; de Kok IMCM
    Gynecol Oncol; 2021 Jan; 160(1):118-127. PubMed ID: 33199028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
    Munshi VN; Perkins RB; Sy S; Kim JJ
    Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
    Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
    Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
    JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study.
    Kaljouw S; Jansen EEL; Aitken CA; de Kok IMCM
    BJOG; 2022 Oct; 129(11):1862-1869. PubMed ID: 35429107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.
    Sawaya GF; Sanstead E; Alarid-Escudero F; Smith-McCune K; Gregorich SE; Silverberg MJ; Leyden W; Huchko MJ; Kuppermann M; Kulasingam S
    JAMA Intern Med; 2019 Jul; 179(7):867-878. PubMed ID: 31081851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.